Order Article Reprints

Benyahia Z, Blackman MCNM, Hamelin L, Zampieri LX, Capeloa T, Bedin ML, Vazeille T, Schakman O, Sonveaux P. In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment. Cancers. 2021; 13(3):569. https://doi.org/10.3390/cancers13030569

Benyahia, Zohra, Marine C. N. M. Blackman, Loïc Hamelin, Luca X. Zampieri, Tania Capeloa, Marie L. Bedin, Thibaut Vazeille, Olivier Schakman, and Pierre Sonveaux. 2021. "In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment" Cancers 13, no. 3: 569. https://doi.org/10.3390/cancers13030569

Benyahia, Z., Blackman, M. C. N. M., Hamelin, L., Zampieri, L. X., Capeloa, T., Bedin, M. L., Vazeille, T., Schakman, O., & Sonveaux, P. (2021). In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment. Cancers, 13(3), 569. https://doi.org/10.3390/cancers13030569